强制液体清除与常规治疗在高危急性肾损伤合并严重液体超负荷重症患者中的比较(FFAKI):一项随机对照先导试验的研究方案
FFAKI是一项多中心、随机、先导性临床试验,招募合并液体超负荷(超过理想体重10%)的急性肾损伤成人重症患者,随机分配至常规治疗或强制液体清除(目标为净液体平衡≥-1 mL/kg/h),主要结局为随机化后5天时的液体平衡,所有患者随访90天,旨在评估开展大型试验的可行性。
要点
- FFAKI为多中心随机先导试验,纳入急性肾损伤合并液体超负荷(超过理想体重10%)的成人重症患者。
- 强制液体清除组以净液体平衡≥-1 mL/kg/h为目标,按低灌注预设标准(乳酸≥4 mmol/L、平均动脉压<50 mmHg或膝盖骨边缘以外的大理石样改变)暂停液体清除。
- 主要结局为随机化后5天液体平衡,次要结局包括平均每日液体平衡、ICU出院时液体平衡、达到中性液体平衡时间、严重不良反应数和方案违背数。
核心结论
- FFAKI试验于2015年10月开始,完成后将提供数据评估在重症患者中开展强制液体清除大型试验的可行性。
- 主要结局将显示实验性干预是否导致液体平衡出现具有临床相关性的差异,该差异可能对急性肾损伤重症患者有益。
研究设计与样本
- FFAKI试验是一项先导、多中心、随机临床试验,招募合并液体超负荷(定义为超过理想体重10%)的急性肾损伤成人重症患者。
- 患者通过隐蔽分配随机至常规治疗或强制液体清除,强制液体清除的治疗目标为净液体平衡≥-1 mL/kg/h。
- 所有患者随访90天。
主要发现
- 主要结局指标为随机化后5天时的液体平衡。
- 次要结局包括平均每日液体平衡、重症监护病房出院时液体平衡、达到中性液体平衡的时间、严重不良反应数量和方案违背数量。
- 液体清除的安全性根据低灌注预设标准持续评估:乳酸≥4 mmol/L、平均动脉压<50 mmHg或膝盖骨边缘以外的大理石样改变;若患者符合其中一项标准,则暂停液体清除直至低灌注缓解。
关键数值与推荐
- 液体超负荷定义为超过理想体重10%。
- 强制液体清除的治疗目标为净液体平衡≥-1 mL/kg/h。
- 低灌注预设标准为乳酸≥4 mmol/L、平均动脉压<50 mmHg或膝盖骨边缘以外的大理石样改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous administration of fluids is an essential part of critical care. While some fluid administration is likely beneficial, there is increasing observational evidence that the development of fluid overload is associated with increased mortality. There are no randomised trials to confirm this association in patients with acute kidney injury. We aim to perform a pilot trial to test the feasibility of forced fluid removal compared to standard care in patients with acute kidney injury and severe fluid overload, the FFAKI trial. METHODS: Then FFAKI trial is a pilot, multicentre, randomised clinical trial recruiting adult intensive care patients with acute kidney injury and fluid overload, defined as more than 10% of ideal bodyweight. Patients are randomised with concealed allocation to either standard care or forced fluid removal with a therapeutic target of negative net fluid balance ≥1 mL/kg/h. The safety of fluid removal is continually evaluated according to predefined criteria of hypoperfusion: lactate ≥4 mmol/L, mean arterial pressure <50 mmHg or mottling beyond the edge of the kneecaps. If patients fulfil one of these criteria, fluid removal is suspended until hypoperfusion has resolved. The primary outcome measure is fluid balance at 5 days after randomisation and secondary outcomes include mean daily fluid balance, fluid balance at discharge from the intensive care unit, time to neutral fluid balance, number of serious adverse reactions and number of protocol violations. All patients are followed for 90 days. DISCUSSION: The FFAKI trial started in October 2015 and, when completed, will provide data to evaluate whether a large trial of forced fluid removal in critically ill patients is feasible. Our primary outcome will show if the experimental intervention leads to a clinically relevant difference in fluid balance, which could prove beneficial in intensive care patients with acute kidney injury. TRIAL REGISTRATION: EudraCT, identifier: 2015-001701-13. Registered on 19 September 2015; ClinicalTrials.gov, identifier: NCT02458157 . Registered on 21 May 2015; Danish Ethics Committee, identifier: H-15009589H. Registered on 22 September 2015; Danish Health and Medicines Authority, identifier: 2015070013. Registered on 11 August 2015.
引用
- Berthelsen RE, Itenov T, Perner A, et al. Forced fluid removal versus usual care in intensive care patients with high-risk acute kidney injury and severe fluid overload (FFAKI): study protocol for a randomised controlled pilot trial. Trials. 2017. PMID: 28438182. doi:10.1186/s13063-017-1935-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。